Health & Fitness
Health and Fitness
Health and Fitness
Tue, February 10, 2009
Mon, February 9, 2009 AMAG Pharmaceuticals, Inc. to Host Conference Call to Discuss Financial Results for the Quarter and Year Ended December 31, 200
LEXINGTON, Mass.--([ BUSINESS WIRE ])--AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced it will report unaudited consolidated financial results for the quarter and year ended December 31, 2008 before the U.S. financial markets open on Friday, February 27, 2009. The announcement will be followed by a conference call at 8:30 a.m. ET during which management will discuss the Company's financial results, business highlights and its development programs.
To access the conference call via telephone, please dial (877) 412-6083 from the United States or (702) 495-1202 for international access. A telephone replay will be available from approximately 10:00 a.m. ET on February 27, 2009 through midnight March 1, 2009. To access a replay of the conference call, dial (800) 642-1687 from the United States or (706) 645-9291 for international access. The passcode for the live call and the replay is 85018091.
An audio webcast of the call will be available through the [ Investors ] section of the Company's website at [ www.amagpharma.com ]. The webcast replay will be available from approximately 10:00 a.m. ET on February 27, 2009 through midnight March 27, 2009.
About AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary technology for the development and commercialization of a therapeutic iron compound to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease.
Feraheme™ (ferumoxytol injection) is being developed for use as an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia and as a diagnostic agent for vascular-enhanced magnetic resonance imaging to assess peripheral arterial disease.
